Biovail Acquires Ativan and Isordil from Wyeth. Publication Date: 02-JUN-03 Publication Title: Business Wire Format: Online - approximately 986 words Company: Biovail Corp. Author: Read this article now Try Goliath Business News – FREE!  You can view this article PLUS... Over 5 million business articles Hundreds of the most trusted magazines, newswires, and journals (see list) Premium business information that is timely and relevant Unlimited Access Now for a Limited Time, try Goliath Business News Free for 7 Days! Tell Me More   Terms and Conditions Purchase this article for $4.95

Description

Business Editors/Health/Medical Writers TORONTO--(BUSINESS WIRE)--June 2, 2003 -- Anxiety treatment Ativan complements Biovail's growing CNS franchise -- Isordil further expands Biovail's cardiovascular product line Biovail Corporation (NYSE:BVF)(TSX:BVF) announced today that it has acquired U.S. rights to the Ativan(R) (lorazepam) and Isordil(R) (isosorbide dinitrate) oral product lines from Wyeth (NYSE:WYE) for $130 million and annual payments pursuant to a three year supply agreement. Sales of Ativan and Isordil in the U.S. were in excess of $50 million in 2002. Ativan is a benzodiazepine, indicated for the management of anxiety disorders or for the short-term relief of anxiety or anxiety associated with depressive symptoms. The market for anxiety treatments was in excess of $11 billion for the 12 months ended December 2002. Isordil is a nitrate indicated for the prevention of angina pectoris due to coronary artery disease. Sales of nitrate products were in excess of $360 million for the 12 months ended December 2002. Biovail...

Looking for additional articles?
Click here to search our database of over 3 million articles.